Vaccine Appears to 'Mop Up' Leukemia Cells Gleevec Leaves Behind, Johns Hopkins Kimmel Cancer Center Study
ScienceDaily (Jan. 10, 2010) — Johns Hopkins Kimmel Cancer Center researchers say preliminary studies show that a vaccine made with leukemia cells may be able to reduce or eliminate the last remaining cancer cells in some chronic myeloid leukemia (CML) patients taking the drug Imatinib mesylate (Gleevec).